Black Diamond Therapeutics, Inc.
BDTX
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The cā¦ read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$4.01
Price-10.69%
-$0.48
1Y
Price
Market Cap
$228.469m
Small
Price/Earnings 3y Avg5y Avg
10.8x
Premium
Premium
Financials Overview
Key metrics over the past few years-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$70.516m
-
1y CAGR-
3y CAGR-
5y CAGREarnings
$14.439m
+120.7%
1y CAGR+48.6%
3y CAGR+43.3%
5y CAGREPS
$0.23
+118.1%
1y CAGR+58.6%
3y CAGR+50.8%
5y CAGRBook Value
$132.610m
$166.385m
Assets$33.775m
Liabilities$16.970m
DebtDebt to Assets
10.2%
3.4x
Debt to EBITDAFree Cash Flow
$17.873m
+128.7%
1y CAGR+52.4%
3y CAGR+43.5%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company